热门资讯> 正文
Day One BiopharmPharmaceuticals宣布以1.08亿美元的价格出售优先审查收件箱
2024-05-30 20:46
- DAY ONE BIOPHARMACEUTICALS(DAWN) 0
- Nuveen Emerging Markets Debt 2022 Target Term Fund(JEMD) 0
- Viracta Therapeutics, Inc.(VIRX) 0
- Day One Biopharmaceuticals (NASDAQ:DAWN) has sold its Priority Review Voucher for $108M to an undisclosed buyer.
- The Co. was awarded the PRV following the U.S. FDA accelerated approval of OJEMDA™.
- Under the Rare Pediatric Disease Priority Review Voucher Program, FDA awards PRVs to sponsors of rare pediatric disease product applications that meet certain criteria.
- As part of the transaction, $8.1M of the total consideration received from the sale of the PRV will be paid to Viracta Therapeutics to fully satisfy PRV related obligations of the Co.’s license agreement with Viracta, dated Dec. 16, 2019.
More on Day One Biopharmaceuticals
- Day One Pharmaceuticals: Ojemda Approval A Big Win, Current Valuation Fair
- Day One slips despite Ojemda approval as BofA says label “not a home run”
- Day One wins FDA nod for brain cancer therapy, Ojemda
- Seeking Alpha’s Quant Rating on Day One Biopharmaceuticals
- Historical earnings data for Day One Biopharmaceuticals
推荐文章
财报前瞻 | 特斯拉Q3营收料重获增长！股价季度内狂涨40%，大行喊话依旧被严重低估
美股机会日报 | 美联储鸽派立场恐生变？沃勒称若10月降息，之后须谨慎行动；诺和诺德、礼来盘前跌约4%
恐慌指数单日飙涨22%！“华尔街一哥”拉响区域银行警报，投资者如何对冲股市波动风险？
海西新药上市时间表顺延
华盛早报 | 恐慌指数飙升！区域银行“坏账”担忧打击美股市场，黄金自2024年初以来涨幅翻倍
美股机会日报 | 50个基点？美联储米兰呼吁大幅降息；蔚来遭遇诉讼，盘前大跌近8%
G20风险监管机构警告：全球加密货币监管存在“重大缺口”
新股暗盘 | 海西新药大涨逾101%！中签一手账面浮盈4375港元
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
